As of 2025-05-25, the Intrinsic Value of Tekla Life Sciences Investors (HQL) is 52.19 USD. This HQL valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 12.35 USD, the upside of Tekla Life Sciences Investors is 322.60%.
The range of the Intrinsic Value is 45.64 - 61.24 USD
Based on its market price of 12.35 USD and our intrinsic valuation, Tekla Life Sciences Investors (HQL) is undervalued by 322.60%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 45.64 - 61.24 | 52.19 | 322.6% |
| DCF (Growth 10y) | 65.02 - 86.53 | 74.08 | 499.9% |
| DCF (EBITDA 5y) | 70.82 - 97.21 | 86.67 | 601.8% |
| DCF (EBITDA 10y) | 93.71 - 129.54 | 114.31 | 825.6% |
| Fair Value | 73.61 - 73.61 | 73.61 | 496.00% |
| P/E | 20.47 - 51.58 | 26.65 | 115.8% |
| EV/EBITDA | (1.15) - 77.86 | 35.97 | 191.2% |
| EPV | (0.76) - (0.89) | (0.82) | -106.7% |
| DDM - Stable | 18.65 - 33.34 | 25.99 | 110.5% |
| DDM - Multi | 20.99 - 30.02 | 24.76 | 100.5% |
| Market Cap (mil) | 356.54 |
| Beta | 3.55 |
| Outstanding shares (mil) | 28.87 |
| Enterprise Value (mil) | 356.54 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.00% |
| Cost of Debt | 5.00% |
| WACC | 6.84% |